White paper issued on rotavirus

16 February 2009

The National Foundation for Infectious Diseases recently released a white paper summarizing a panel discussion of national pediatric  infectious disease experts on rotavirus.  The paper, which was  co-sponsored by US drug major Merck & Co, addresses the latest  scientific information available on rotavirus, including epidemiology,  classification, prevention and treatment of the disease.  In the midst  of the rotavirus season, this paper may serve as a valuable resource to  your readers.  For a free copy of the white paper, visit:  http://www.nfid.org/pdf/rotavirus_paper.pdf.

Rotavirus is a leading cause of acute gastroenteritis in infants and  young children worldwide, infecting nearly all children by the age of 5.  The most severe cases occur among children 6 to 24 months of age, with  symptoms including fever, vomiting and watery diarrhea.  In serious  cases, repeated episodes of diarrhea or vomiting can lead to loss of  fluid and electrolytes, placing the child at risk for severe dehydration  and death.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >




Today's issue

Company Spotlight